Myasthenia gravis: diagnosis and treatment

Acquired Myasthenia Gravis (MG) is a very rare disease, with prevalence rates in the US population reaching around 20 per 100,000. Muscle weakness is a symptom of an autoimmune illness, which worsens with exercise and improves with rest. Extrinsic Ocular Muscles (EOMs) involvement is the first symptom in around two-thirds of patients, and it generally progresses to include additional bulbar muscles and limb musculature, resulting in Generalised Myasthenia Gravis (GMG) [1]. About 10% of myasthenia gravis individuals have symptoms restricted to EOMs, resulting in a syndrome known as Ocular Myasthenia Gravis (OMG). Myasthenia gravis appears to be influenced by gender and age. Female to male ratio is around 3:1 under 40 years of age; however, it is nearly equal between 40years and 50 years of age, as well as throughout puberty. It is more frequent in guys over the age of 50. Childhood Myasthenia Gravis (MG) is rare in Europe and North America, accounting for just 10% to 15% of all MG cases. However, in Asian nations, up to 50% of patients present before the age of 15, with primarily ocular symptoms.